ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF). The study ...

For the first time, a new paper in Nature Biotechnology discloses the raw experimental data and the preclinical and clinical evaluation of Insilico Medicine's potentially first-in-class TNIK ...

The novel molecule to treat IPF was designed by the company's generative AI software after it was given the objective of inhibiting a protein called TNIK, which has never been targeted before for ...

which analyzed vast omics and clinical datasets to identify TNIK (TRAF2 and NCK-interacting kinase) as a promising novel target for IPF. Building on this discovery, researchers used Chemistry42 ...

To date, the small-molecule TNIK inhibitor dubbed ISM001-055 has gone on to show improvements in lung function among IPF patients in a 12-week, placebo-controlled phase 2a trial, while also ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC ...

Notably, the study, for the first time, validated the biological mechanism of treating IPF by targeting TNIK—a novel target identified through generative AI—in a clinical setting, and ...